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Abstract
Background: In humans, interferon-α treatment for chronic viral hepatitis is a well-recognized clinical model for inflammation-
induced depression, but the molecular mechanisms underlying these effects are not clear. Following peripheral administration 
in rodents, interferon-α induces signal transducer and activator of transcription-1 (STAT1) within the hippocampus and 
disrupts hippocampal neurogenesis.
Methods: We used the human hippocampal progenitor cell line HPC0A07/03C to evaluate the effects of 2 concentrations 
of interferon-α, similar to those observed in human serum during its therapeutic use (500 pg/mL and 5000 pg/mL), on 
neurogenesis and apoptosis.
Results: Both concentrations of interferon-α decreased hippocampal neurogenesis, with the high concentration also increasing 
apoptosis. Moreover, interferon-α increased the expression of interferon-stimulated gene 15 (ISG15), ubiquitin-specific 
peptidase 18 (USP18), and interleukin-6 (IL-6) via activation of STAT1. Like interferon-α, co-treatment with a combination of 
ISG15, USP18, and IL-6 was able to reduce neurogenesis and enhance apoptosis via further downstream activation of STAT1. 
Further experiments showed that ISG15 and USP18 mediated the interferon-α-induced reduction in neurogenesis (potentially 
through upregulation of the ISGylation-related proteins UBA7, UBE2L6, and HERC5), while IL-6 mediated the interferon-
α-induced increase in apoptosis (potentially through downregulation of aquaporin 4). Using transcriptomic analyses, 
we showed that interferon-α regulated pathways involved in oxidative stress and immune response (e.g., Nuclear Factor 
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(erythroid-derived 2)-like 2 [Nrf2] and interferon regulatory factor [IRF] signaling pathway), neuronal formation (e.g., CAMP 
response element-binding protein [CREB] signaling), and cell death regulation (e.g., tumor protein(p)53 signaling).
Conclusions: We identify novel molecular mechanisms mediating the effects of interferon-α on the human hippocampus 
potentially involved in inflammation-induced neuropsychiatric symptoms.
Keywords: apoptosis, depression, inflammation, interferon-alpha, neurogenesis
Introduction
Initially identified for its anti-viral properties, interferon (IFN)-α 
is a pleiotropic molecule and a major mediator of innate and 
adaptive immune responses (Pestka, 2000). In addition to its 
immuno-modulatory properties, IFN-α has been shown to have 
a number of effects on the brain, ranging from increased neu-
rotoxicity (Alboni et al., 2013) to the development of behavioral 
phenotypes, in both human and animal models (Felger et  al., 
2007; Hepgul et  al., 2016a). In particular, IFN-α treatment has 
been shown to cause depressive symptoms as well as other 
neuropsychiatric adverse effects, such as anxiety, sleep disor-
ders, and memory impairment, when administered to patients 
as a treatment for chronic viral hepatitis (Raison et  al., 2005). 
However, the molecular mechanisms underlying these effects 
have not been completely elucidated yet.
Studies in rodents have shown that peripheral IFN-α induces 
changes in the expression of IFN-stimulated genes (ISGs) within 
discrete brain regions, including the hippocampus (Wang et al., 
2008). Previous research has also demonstrated that peripheral 
administration of IFN-α alters neurogenesis in the hippocampus 
of adult rodents in terms of both cell proliferation and neuronal 
differentiation (Zheng et al., 2014). Taken together, these find-
ings indicate that the hippocampus may be affected by IFN-α 
and that the psychiatric side effects caused by IFN-α therapy 
might be a consequence of disrupted neurogenesis or neuronal 
function in the hippocampus. Indeed, there is evidence that IFN-
α and other cytokines can penetrate the more permeable areas 
of the blood-brain barrier to affect brain signaling (Zheng et al., 
2014). Moreover, some other cytokines have been shown to alter 
neurogenesis (Borsini et al., 2015). In humans, adult neurogen-
esis principally occurs in the subventricular zone of the lateral 
ventricles and the subgranular zone of the dentate gyrus of the 
hippocampus (Kempermann et  al., 2015). To our knowledge, 
there have been no studies investigating the effects of IFN-α on 
human hippocampal neurogenesis or examining the potential 
molecular mechanisms underlying these effects.
Previous data have shed light on some molecular pathways 
activated by IFN-α in the brain and highlighted their potential 
involvement in the development of IFN-α-induced psychopa-
thology. IFN-α binds to its interferon alpha/beta receptor, lead-
ing to the phosphorylation of 2 transcription factors, STAT1 and 
STAT2. Phosphorylated STAT1 and STAT2 then migrate into the 
nucleus and induce the expression of ISGs, which mediates the 
biological effects of IFN-α (Wang et al., 2008). Indeed, we have 
recently shown that the IFN-stimulated genes, ISG15 and ubiq-
uitin-specific peptidase 18 (USP18), are among the most upreg-
ulated genes in the blood of patients following in vivo IFN-α 
treatment (Hepgul et al., 2016b). Similarly, via activation of STAT 
signaling pathways, IFN-α can induce inflammatory cytokines, 
including IL-6 (Taga and Kishimoto, 1997). Indeed, there is in 
vitro evidence that neurons in the hippocampus of rodents 
respond to IFN-α with an increase in ISGs, such as STAT1, ISG15, 
USP18, and IL-6 (Wang et al., 2008; Jin et al., 2012).
To dissect the molecular mechanisms underlying the puta-
tive effects of IFN-α on human hippocampal neurogenesis, we 
here analyze the effect of 2 distinct concentrations of IFN-α (500 
and 5000 pg/mL, similar to serum concentrations of patients 
receiving IFN-α for chronic viral hepatitis) (Bruno et  al., 2004; 
Francois et al., 2010) on an immortalized human hippocampal 
progenitor cell line previously established as an in vitro model 
of human neurogenesis (Zunszain et  al., 2012; Anacker et  al., 
2013a). We also test the ability of IFN-α to induce STAT1, ISG15, 
USP18, and IL-6 in these cells and investigate whether these 
proteins are mechanistically involved in the effects of IFN-α. 
Finally, we conduct transcriptomic analyses to shed light on 
novel molecular signaling pathways regulated by IFN-α in hip-
pocampal neurons.
Methodology
Cell Culture
We used our established in vitro model of human hippocampal 
neurogenesis, the multipotent human hippocampal progeni-
tor cell line HPC0A07/03C (provided by ReNeuron, Surrey, UK) 
(Anacker et al., 2011, 2013a, 2013b; Zunszain et al., 2012; Horowitz 
et al., 2015; Borsini et al., 2017). This model was previously vali-
dated using a hippocampal newborn neuron specific marker, 
Prospero homeobox protein 1 (Anacker et al., 2013a). Cells were 
left to proliferate in the presence of growth factors (Epidermal 
Growth Factor [EGF], basic Fibroblast Growth Factor [bFGF]) and 
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4-hydroxytamoxifen (4-OHT). Differentiation was initiated by 
removal of the growth factors and 4-OHT. Detailed information 
on this cell line and culture conditions can be found in our pre-
vious publications and in the supplementary Materials.
Differentiation Assays
To assess changes in neuronal differentiation, HPC0A07/03C 
cells were plated into clear 96-well plates (Nunclon) at a den-
sity of 1.2 x 104 cells/well. Twenty-four hours later, cells were cul-
tured in the presence of EGF, bFGF, and 4-OHT and with IFN-α, or 
other proteins/drugs for 3 days (see supplementary Materials). 
After this initial proliferation phase, cells were washed and then 
cultured in media containing IFN-α or the same proteins/com-
pounds but without growth factors or 4-OHT for 7 subsequent 
days. This paradigm was used for all experiments. Finally, cells 
were rinsed with warm PBS and fixed with 4% paraformalde-
hyde (PFA) for 20 minutes at room temperature.
Immunocytochemistry
Differentiation into immature and mature neurons was assessed 
with doublecortin (DCX) (Alexa 488 donkey anti-rabbit; 1:1000) 
and microtubule-associated protein 2 (MAP2) (Alexa donkey 
555 anti-mouse, 1:1000, Invitrogen), respectively. Apoptotic 
cells were examined using caspase 3 (CC3) (Alexa 488 donkey 
anti-rabbit; 1:1000; Invitrogen). DAPI dye was used to label all 
cells. The number of positive cells over total DAPI positive cells 
was counted using an insight automated imaging platform 
(CellInsight) (see supplementary Materials). See supplementary 
Figure 1 for representative images.
Multiplex Cytokines Measurement
For cytokines measurement, cell supernatants of differenti-
ated cells were run on the Human ProInflammatory Multileplex 
Very-Sensitive Kit from Meso Scale Discovery according to the 
manufacturers’ instructions (see supplementary Materials) and 
analyzed on the SECTOR Imager Meso Scale Discovery device.
RNA Isolation, cDNA Synthesis, and Quantitative 
Real-Time PCR (qPCR) Analysis
RNA of differentiated cells was isolated using the RNeasy Micro 
Kit (Qiagen) following the manufacturer’s instructions and 
frozen at -80°C. Then 1 µg total RNA was reversed-transcribed 
by Superscript III enzyme (Life Technologies) according to the 
manufacturers’ instructions (see supplementary Materials). 
Subsequently, both target and housekeeping gene expression 
levels were analyzed by TaqMan qRT-PCR instrument (CFX384 
real time system, Bio-Rad) using the iScript one-step RTPCR kit 
for probes (Bio-Rad) (see supplementary Materials).
Microarray Analysis
Microarray assays were performed following the protocol in the 
Affymetrix GeneChip Expression Analysis technical manual 
(Affymetrix), as previously described (Anacker et  al., 2013a). 
For gene expression data, CEL files were imported into Partek 
Genomics Suite V6.6 for data visualization and quality con-
trol and statistical analyses. Ingenuity Pathway Analysis (IPA) 
Software was used to identify regulation of molecular signaling 
pathways. Seventeen genes were validated using Real Time PCR 
analyses, as described above.
Statistical Analysis
Each experiment was replicated in at least 3 independent 
cultures (biological replicates). All statistical analyses were 
performed with GraphPad Prism 6.00. One-way ANOVA with 
Newman–Keuls’s posthoc test was used for multiple com-
parisons among treatment groups. Data are presented as 
mean ± SEM, and P values < .05 were considered significant.
Results
IFN-α Decreases Neurogenesis and Increases 
Apoptosis in Human Hippocampal Precursor Cells
Cells were treated with IFN-α (500 pg/mL or 5000 pg/mL) over a 
period of 10 days (3 days of proliferation followed by 7 days of 
differentiation). We found a significant reduction in the num-
ber of DCX+ cells (immature neurons) by both concentrations of 
IFN-α (-12%; Figure 1a). We also found that the number of MAP2+ 
cells (mature neurons) was significantly reduced by both condi-
tions (-21% and -18%, respectively) (Figure 1b).
IFN-α at 5000 pg/mL, but not at 500 pg/mL, also significantly 
increased the number of apoptotic cells (CC3+) and the number 
of apoptotic cells over the pool of newly mature neurons (CC3+/
MAP2+) (respectively, +12%, Figure 1c; and +18%, Figure 1d).
IFN-α Increases STAT1, ISG15, and USP18 mRNA 
Gene Expression, and IL-6 Protein
Previous evidence has reported that STAT1, ISG15, and USP18 are 
among the most upregulated genes in mouse neurons following 
stimulation with IFN-α (Wang et al., 2008) as well as in the blood 
of patients taking IFN-α (Hepgul et al., 2016b). We wanted to test 
whether in vitro treatment with IFN-α was also able to induce 
those genes in human hippocampal cells. We indeed demon-
strated that both concentrations of IFN-α (500 and 5000 pg/mL) 
significantly increased mRNA gene expression of STAT1 (fold 
change [fc] = 2.7 and 3.1, respectively), ISG15 (fc = 2.1 and 3.3), and 
USP18 (fc = 2.1 and 3.4) (Figure 1e-g).
In addition, we sought to characterize the effects of IFN-α on 
cytokine secretion in the supernatant of these cells. We focused 
our analysis on cytokines known to be regulated by IFN-α: 3 that 
are stimulated (IL-6, IL-8, and IFN-γ; Bonaccorso et al., 2001) and 
2 that are inhibited (IL-10 and IL-13; Feng et al., 2002; Sugimoto 
et al., 2005). However, we found no effects of the low concen-
tration of IFN-α (500 pg/mL) on any of the cytokines, which 
were all expressed at low levels in the supernatant (<3 pg/mL). 
At the high concentration of IFN-α (5000 pg/mL), only IL-6 pro-
tein expression was significantly upregulated compared with 
unstimulated cells (4.9 pg/mL ± 0.1 vs 1.7 pg/mL ± 0.03, P < .0001).
Cotreatment with ISG15, USP18, and IL-6 Mimics the 
Effect of IFN-α on Neurogenesis and Apoptosis
To investigate the potential mechanisms involved in effects 
of IFN-α on neurogenesis and apoptosis, we focused on ISG15, 
USP18, and IL-6, the 3 molecules induced by treatment with IFN-
α. Cells were cotreated with ISG15 (10 pg/μL), USP18 (10 pg/μL), 
or IL-6 (5 pg/μL) recombinant proteins, either alone or in com-
bination (see supplementary Materials for justification of the 
concentrations).
Similar to what we found with IFN-α, we found a significant 
reduction in DCX+ cells following cotreatment with all proteins 
(-15%, Figure  2a). Moreover, we found a significant reduction 
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Figure 1. Interferon (IFN)-α reduces differentiation, increases apoptosis, and upregulates signal transducer and activator of transcription-1 (STAT1), interferon-stim-
ulated gene 15 (ISG15), and ubiquitin-specific peptidase 18 (USP18) gene expression. IFN-α (500 and 5000 pg/mL) decreased doublecortin (DCX) + (a) and microtubule-
associated protein 2 (MAP2)+ cells (b). IFN-α 5000 pg/mL increased both caspase 3 (CC3)+ cells (c) and CC3+ /MAP2+ cells (d). IFN-α (500 and 5000 pg/mL) increased STAT1 
(e), ISG15 (f), and USP18 (g) gene expression. Three independent experiments were conducted on independent cultures (n = 3). Data are shown as mean  ±  SEM. 1-way 
ANOVA, Newman–Keuls’ posthoc test *P < .05, **P < .01, ***P < .001, ****P < .0001, compared with vehicle treatment or as indicated.
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following treatment with ISG15 alone (-18%, Figure 2a), but not 
with USP18 or IL-6 alone (Figure 2a). This shows that ISG15, but 
not USP18 or IL-6, is involved in the IFN-α-induced reduction in 
DCX+ cells.
Again, similar to what we found with IFN-α, we also found 
a significant reduction in MAP2+ cells following cotreatment 
with all proteins (-19%, Figure  2b). Moreover, we found a sig-
nificant reduction following treatment with ISG15 alone (-17%, 
Figure  2b) or USP18 alone (-18%, Figure  2b), but not with IL-6 
alone (Figure 2b). This shows that ISG15 and USP18, but not IL-6, 
are involved in the IFN-α–induced reduction in MAP2+ cells.
With regards to apoptosis, again similarly to what we found 
with IFN-α, we found a significant increase in CC3+ and CC3+/
MAP2+ cells following cotreatment with all proteins (+15% and 
+19%, Figure 2c-d). Moreover, we found a significant increase in 
CC3+ and CC3+/MAP2+ cells following treatment with IL-6 (+14% 
and +16%, Figure 2c-d), but we found a decrease in the number of 
CC3+ cells with USP18 (-15%, Figure 2c) and no effect with ISG15 
treatment (Figure 2c). This shows that IL-6, but not ISG15 and 
USP18, is involved in the IFN-α-induced increase in apoptosis. 
This conclusion is further supported by additional mechanis-
tic experiments where we showed that an anti-IL-6 monoclonal 
antibody (0.10 μg/mL) prevents the IFN-α-induced increase in 
apoptosis, but not the reduction in neurogenesis (Figure 3a-d).
Treatment with a STAT1 Inhibitor Reverts the 
Effects of IFN-α on Neurogenesis and Apoptosis by 
Preventing the Upregulation of ISG15, USP18, and IL-6
Having described such marked effects of IFN-α on neurogenesis 
and apoptosis, and the possible involvement of STAT1, ISG15, 
USP18, and IL-6 as potentially relevant mechanisms, we next 
investigated if and how these mechanisms were inter-con-
nected. Therefore, cells were treated with IFN-α (500 and 5000 
pg/mL) either alone or in combination with a STAT1 inhibitor, 
fludarabine (10  nM). We found that cotreatment with fludara-
bine abolished the IFN-α-induced reduction in DCX+ (Figure 4a) 
and MAP2+ cells (Figure  4b) at both concentrations of IFN-α. 
Similarly, cotreatment with fludarabine abolished the IFN-
α-induced increase in CC3+ (Figure  4c) and CC3+/MAP2+ cells 
Figure 2. Cotreatment with interferon-stimulated gene 15 (ISG15), ubiquitin-specific peptidase 18 (USP18), and interleukin (IL)-6 mimics the effect of interferon (IFN)-α 
on neurogenesis and apoptosis. ISG15 and all proteins reduced doublecortin (DCX)+ cells (a). ISG15, USP18, and all proteins reduced microtubule-associated protein 
2 (MAP2)+ cells (b). USP18 also decreased caspase 3 (CC3)+ cells, whereas IL-6 and all proteins significantly increased both CC3+ and CC3/MAP2+ cells (c-d). Three 
independent experiments were conducted on independent cultures (n = 3). Data are shown as mean ± SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P < .05, **P < .01, 
***P < .001, compared with vehicle treatment or as indicated.
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(Figure  4d) seen upon the high IFN-α concentration (5000 pg/
mL). Finally, we also found that fludarabine blocked the upregu-
lation of ISG15, USP18, and IL-6 (Figure 4e-g), thus indicating that 
STAT1 activation is required for the IFN-α-induced upregulation 
of these 3 molecules.
Treatment with a STAT1 Inhibitor Prevents the Effect 
of ISG15 on Neurogenesis and of IL-6 on Apoptosis
We then wanted to investigate if STAT1 is involved also in the 
downstream mechanisms by which ISG15, USP18, and IL-6, 
respectively, reduce neurogenesis and increase apoptosis. We 
again treated cells with a cotreatment with ISG15, USP18, and 
IL-6, or with these proteins alone, and with or without fludara-
bine. We found that fludarabine blocked the reduction in MAP2+ 
cells induced by the cotreatment and by ISG15 alone (Figure 5b), 
as well as the increase in CC3+ and CC3+/MAP2+ cells induced 
by the cotreatment and by IL-6 alone (Figure  5c-d). However, 
fludarabine did not prevent the reduction in MAP2+ cells by 
USP18 (Figure  5b). This experiment suggests that the down-
stream effects of ISG15 and IL-6 on, respectively, neurogenesis 
and apoptosis are also mediated by further STAT1 activation, 
while the effects of USP18 on neurogenesis are mediated by a 
different mechanism (see supplementary Figure  4 for a sum-
mary of the findings).
Treatment with IFN-α, ISG15, and All Proteins 
Increase UBA7, UBE2L6, and HERC5 Gene Expression 
via Activation of STAT1 Protein
Having demonstrated that IFN-α can reduce neurogenesis via 
ISG15-dependent STAT1 activation, we decided to investigate 
which downstream mechanisms STAT1 can modulate once 
induced by ISG15. We focussed on 3 genes that were among the 
most upregulated in the transcriptomic analysis (see below) by 
both concentrations of IFN-α: ubiquitin like modifier activating 
enzyme 7 (UBA7), ubiquitin conjugating enzyme E2 L6 (UBE2L6), 
and HECT and RLD domain containing E3 ubiquitin protein 
Figure 3. Interleukin (IL)-6A prevents the effects of interferon (IFN)-α on apoptosis. Treatment with IL-6A prevented the increase in caspase 3 (CC3)+ and CC3/micro-
tubule-associated protein 2 (MAP2)+ cells detected upon IFN-α 5000 pg/mL (c-d). Three independent experiments were conducted on independent cultures (n = 3). Data 
are shown as mean ± SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P < .05, **P < .01, ****P < .0001, compared with vehicle treatment or as indicated.
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Figure 4. Treatment with a signal transducer and activator of transcription-1 (STAT1) inhibitor reverts the effects of interferon (IFN)-α on neurogenesis and apoptosis by 
preventing the upregulation of interferon-stimulated gene 15 (ISG15), ubiquitin-specific peptidase 18 (USP18), and interleukin (IL)-6. Fludarabine prevented the decrease 
in doublecortin (DCX)+ and microtubule-associated protein 2 (MAP2)+ cells caused by IFN-α (500 and 5000 pg/mL) (a-b), as well as the decrease in caspase 3 (CC3)+ and 
CC3+/MAP2+ cells detected upon IFN-α 5000 pg/mL (c-d). Fludarabine prevented the increase in ISG15 (e) and USP18 (f) genes and IL-6 protein expression (g) observed 
upon IFN-α (500 and 5000 pg/mL). Three independent experiments were conducted on independent cultures (n = 3). Data are shown as mean ± SEM. 1-way ANOVA, New-
man–Keuls’ posthoc test **P < .01, ***P < .001, ****P < .0001, compared with vehicle treatment or as indicated.
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ligase 5 (HERC5) (supplementary Table 3). These molecules, also 
defined as the main E1, E2, and E3 enzymes involved in ISG15 
ISGylation (Zhang and Zhang, 2011), are able to target distinct 
cyclin proteins (Feng et al., 2008) known for their ability to regu-
late both cell proliferation and differentiation (Kabadi et  al., 
2012) and therefore represent a possible mechanism mediat-
ing IFN-α-dependent reduction of neurogenesis. Indeed, and 
in accordance with the microarray results, IFN-α increased 
UBA7, UBE2L6, and HERC5 gene expression measured by qPCR 
(Figure 6a-c), and this effect was blocked by cotreatment with 
fludarabine (Figure 6a-c).
We then wanted to test whether ISG15 was able to induce 
UBA7, UBE2L6, and HERC5, and whether such effect was medi-
ated by further downstream STAT1 activation. As before, cells 
were treated for 3 days of proliferation followed by 7 days of dif-
ferentiation, with ISG15 or cotreatment with ISG15, USP18, and 
IL-6, either alone or in combination with fludarabine. Results 
showed a significant increase in UBA7, UBE2L6, and HERC5 
upon treatment with ISG15 alone or with cotreatment with 
all proteins (Figure  6d-f). Most interestingly, this upregulation 
was prevented by fludarabine (Figure 6d-f). In separate experi-
ments, USP18 alone and IL-6 alone did not modulate these 
genes (Figure 6d-f). These findings suggest that STAT1-mediated 
upregulation of UBA7, UBE2L6, and HERC5 is a downstream 
mechanism involved in the ISG15-dependent pathway by which 
IFN-α reduces neurogenesis.
Treatment with IFN-α or IL-6 Decreases AQP4 Gene 
Expression via Activation of STAT1 Protein
Having demonstrated that only the high concentration of IFN-
α (5000 pg/mL) alters apoptosis via IL-6-dependent STAT1 pro-
tein activation, we decided to investigate which subsequent 
mechanisms may be involved. We focussed on one gene that 
was among the most downregulated in the transcriptomic (see 
below) by the high concentration of IFN-α, AQP4 (Table S2). AQP4 
is important for suppressing neuronal cell death, possibly by 
involving p53-dependent signaling (Kong et al., 2008; Bao et al., 
2012). Indeed, and in accordance with the microarray results, 
only IFN-α 5000 pg/mL significantly decreased AQP4 gene 
expression measured by qPCR (Figure  7a), and this effect was 
blocked by cotreatment with fludarabine (Figure 7a).
We then wanted to test whether IL-6 was involved in the 
AQP4 gene expression downregulation induced by the high dose 
of IFN-α (5000 pg/mL). Indeed, results showed that the anti-
IL-6 antibody blocked the reduction in AQP4 induced by IFN-α 
(Figure 7b). Moreover, both IL-6 alone and the cotreatment with 
IL-6, ISG15, and USP18 induce a significant downregulation of 
AQP4 (fc = -1.5 and = -1.6, respectively; Figure  7c); this effect 
was counteracted by fludarabine (Figure 7c). In separate experi-
ments, ISG15 alone and USP18 alone did not modulate AQP4 
(Figure 7c). These findings suggest that STAT1-mediated down-
regulation of AQP4 is a downstream mechanism involved in the 
IL-6-dependent pathway by which IFN-α increases apoptosis.
IFN-α Modulates Signaling Pathways Involved in 
Cell Development, Cell Death, Oxidative Stress, and 
Inflammatory Response
To further identify the molecular mechanisms potentially 
involved in the effects of IFN-α on neurogenesis and apoptosis, 
we next analyzed gene expression changes by transcriptomics 
upon IFN-α treatment at the same time point (3  days of pro-
liferation followed by 7 days of differentiation) as our previous 
Figure  5. Treatment with a signal transducer and activator of transcription-1 
(STAT1) inhibitor prevents the effect of interferon-stimulated gene 15 (ISG15) on 
neurogenesis and of interleukin (IL)-6 on apoptosis. Fludarabine prevented the 
decrease in microtubule-associated protein 2 (MAP2)+ cells caused by ISG15 and 
all proteins (b), as well as the increase in caspase 3 (CC3)+ and CC3+/MAP2+ cells 
detected upon treatment with IL-6 (c) and all proteins (d). Three independent 
experiments were conducted on independent cultures (n = 3). Data are shown 
as mean ± SEM. One-way ANOVA, Newman–Keuls’ posthoc test *P < .05, **P < .01, 
****P < .0001, compared with vehicle treatment or as indicated.
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Figure 6. Treatment with interferon (IFN)-α, interferon-stimulated gene 15 (ISG15), and all proteins increase UBA7, UBE2L6, and HERC5 gene expression via activation of 
signal transducer and activator of transcription-1 (STAT1) protein. IFN-α (500 and 5000 pg/mL) increased UBA7 (a), UBE2L6 (b), and HERC5 (c) gene expression, whereas 
cotreatment with fludarabine prevented such upregulation (a-c). ISG15 and all proteins induced UBA7 (d), UBE2L6 (e), and HERC5 (f). Cotreatment with either ISG15 or all 
proteins and fludarabine prevented such increase (d-f). Three independent experiments were conducted on independent cultures (n = 3). Data are shown as mean ± SEM. 
One-way ANOVA, Newman–Keuls’ posthoc test **P < .01, ***P < .001, ****P < .0001, compared with vehicle treatment or as indicated.
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immunocytochemistry experiments. Overall, IFN-α modulated 
885 genes, of which 155 genes were regulated only by the lower 
concentration (500 pg/mL), 530 genes only by the high concen-
tration (5000 pg/mL), and 200 genes by both concentrations (sup-
plementary Figure 2a). The complete gene expression analysis is 
presented in supplementary Tables 1 to 3, whereas the network 
analysis is presented in supplementary Figure 3 and further dis-
cussed in supplementary Materials.
We also conducted a successful qPCR validation of 17 genes 
up- or downregulated in the transcriptomics analyses, chosen 
because of their association with neurogenesis (tryptophan 
hydroxylase 1, trifoil factor 3, S100 calcium binding protein A13, 
aldo-keto reductase family 7 member A3, and transmembrane 
protein 86A) (supplementary Table 4), cell death and cell cycle 
progression (cyclin D1, histone deacetylase 5, caspase 1, P53-
Induced Death Domain Protein 1, and AQP4) (supplementary 
Table S4), and interferon signaling (ISG15, USP18, STAT1, IRF7, 
UBA7, UBE2L6, and HERC5) (supplementary Table 5), and found 
a very high correlation between the fold-changes detected by 
Affymetrix and those detected by qPCR (r = 0.99; supplementary 
Figure 2b).
We also conducted a pathway analysis focusing our attention 
particularly on pathways involved in oxidative stress, neuronal 
formation, cell death and immune response (supplemental 
Table 6). Fifty-six pathways were significantly regulated only by 
the lower concentration of IFN-α (500 pg/mL) (which, as shown 
Figure 7. Treatment with interferon (IFN)-α, interleukin (IL)-6, and all proteins decrease AQP4 gene expression via activation of signal transducer and activator of 
transcription-1 (STAT1) protein. IFN-α 5000 pg/mL downregulated AQP4 gene expression, whereas cotreatment with IFN-α 5000 pg/mL and fludarabine prevented such 
downregulation (a). IL-6A blocked the reduction in AQP4 seen upon IFN-α 5000 pg/mL (b). Treatment with IL-6 and all proteins decreased AQP4 gene expression, whereas 
cotreatment of IL-6 or all proteins with fludarabine prevented the reduction in AQP4 gene expression (c). Three independent experiments were conducted on inde-
pendent cultures (n = 3). Data are shown as mean ± SEM. 1-way ANOVA, Newman–Keuls’ posthoc test *P < .05, ***P < .001, compared with vehicle treatment or as indicated.
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above, reduces neurogenesis but does not increase apoptosis). 
Of particular note are the Nuclear Factor (erythroid-derived 
2)-like 2 (Nrf2)-mediated Oxidative Stress Response, endothelial 
Nitric Oxide Synthase signaling, Serotonin Receptor Signaling, 
and the Serotonin and Melatonin Biosynthesis pathways. 
Recent data indicate that both the Nrf2 and endothelial Nitric 
Oxide Synthase signaling involved in the regulation of antioxi-
dant proteins against oxidative damage play an essential role 
in governing neuronal cell fate (Chen et  al., 2005; Karkkainen 
et al., 2014). Similarly, previous evidence has shown that altera-
tion in serotonin and melatonin signaling is also associated 
with impairments in cell proliferation and neuronal generation 
(Radley and Jacobs, 2002; Manda and Reiter, 2010; Klempin et al., 
2013).
Additionally, 188 pathways were regulated only by the high 
concentration of IFN-α (5000 pg/mL) (which, as shown above, is 
the only one that increases apoptosis) (supplemental Table 6). 
Of particular note are the p53 signaling, Transforming Growth 
Factor-β signaling, Cyclin-dependent Kinase5 signaling, and FGF 
signaling pathways. In particular, p53 signals have been linked 
to cell cycle arrest and apoptosis and are known to be activated 
in response to DNA damage (Thotala et  al., 2012). Moreover, 
modulation of distinct phases of the cell cycle by Transforming 
Growth Factor-β, Cyclin-dependent Kinase5, and FGF signals has 
been associated with significant alteration in neuronal differ-
entiation (Alexander et al., 2004; He et al., 2014; Woodbury and 
Ikezu, 2014).
Finally, high and low concentrations of IFN-α (500 and 5000 
pg/mL) modulated 165 common pathways (supplemental 
Table S6), among which the Cyclic Adenosine-Monophosphate 
Response Element Binding Protein (CREB) Signaling in Neurons 
and the non-canonical Wnt/Ca+ pathway, associated with cell 
differentiation, as well as the Activation of IRF by Cytosolic 
Pattern Recognition Receptors and the Protein Ubiquitination 
Pathway, involved in the inflammatory response. CREB signaling 
has a well-established role in mediating both brain development 
and neuronal formation (Nakagawa et al., 2002). Similarly, Wnt/
Ca+ signaling is part of the mechanisms regulating neuronal 
motility, regeneration, and plasticity (Zheng and Poo, 2007). 
Finally, protein ubiquitination and IRF signaling are known not 
only to crucially mediate the antiviral response but also to regu-
late cell growth, proliferation, and differentiation (Feng et  al., 
2008; Baruch et al., 2014).
Discussion
In this study, we provide the first evidence that IFN-α regulates 
human hippocampal neurogenesis and apoptosis, and we iden-
tify novel molecular mechanisms that underlie these effects 
and that are thus potentially relevant for inflammation-induced 
neuropsychiatric symptoms. We show in vitro that 2 concentra-
tions of IFN-α (500 and 5000 pg/mL), similar to the lowest and the 
highest serum concentrations found in patients receiving IFN-α 
for chronic viral hepatitis, reduce human neurogenesis and the 
high concentration also increases human hippocampal apopto-
sis. We also demonstrate that both concentrations upregulate 2 
IFN-α-stimulated genes, ISG15 and USP18, via STAT1-dependent 
mechanisms, and that either of these molecules alone can 
induce the same reduction in neurogenesis induced by IFN-
α. In addition, only the high concentration of IFN-α enhances 
IL-6 protein expression, and in turn IL-6 alone can induce the 
same increase in apoptosis induced by IFN-α. At the molecular 
level, treatment with IFN-α regulates gene expression pathways 
involved in oxidative stress (e.g., Nrf2), immune responses (e.g., 
IRF signaling pathway), neuronal formation (e.g., CREB signal-
ing), and cell death regulation (e.g., p53 signaling).
This study identifies ISG15 and USP18 as potential media-
tors of the IFN-α-induced reduction of human neurogenesis. 
Previous studies have shown that systemic injection of IFN-α 
reduces cell proliferation (Kaneko et al., 2006; Zheng et al., 2014) 
and neurogenesis (Zheng et  al., 2014) in the dentate gyrus of 
adult rodents. Moreover, studies have also reported an increase 
in STAT1, ISG15, and USP18 gene expression in parenchymal 
neurons of mice receiving IFN-α treatment (Wang et al., 2008). 
We have previously confirmed the upregulation of these genes 
in the blood of patients treated with IFN-α for chronic viral hep-
atitis (Hepgul et al., 2016b), and we now show that in vitro treat-
ment with IFN-α has the same effects in human hippocampal 
progenitors. In addition, we show that IFN-α upregulates ISG15 
and USP18 via STAT1, and that, in turn, each of these 2 proteins 
alone can mimic the effects of IFN-α on neurogenesis.
Subsequently, we also show that ISG15, but not USP18 and 
IL-6, induces UBA7, UBE2L6, and HERC5 genes via further down-
stream activation of STAT1 (see supplementary Figure  4 for a 
summary of the findings). UBA7, UBE2L6, and HERC5 bind to 
ISG15 in the process of ISGylation (Zhang and Zhang, 2011), 
required for the biological action of ISG15, and they also inde-
pendently target cyclin proteins regulating cell proliferation and 
differentiation (Feng et al., 2008). ISG15 ISGylation also modu-
lates Nrf2-mediated signaling (Komatsu et al., 2010; Nakashima 
et al., 2015), which protects against oxidative damage, a relevant 
mechanism in IFN-α-induced neuronal toxicity (Alboni et  al., 
2013). Indeed, we also found that IFN-α downregulates Nrf2-
mediated signaling pathway in the transcriptomics analysis. 
Taken together, these findings identify STAT1-mediated upregu-
lation of UBA7, UBE2L6, and HERC5 as a potential mechanism in 
the ISG15-dependent reduction in neurogenesis by IFN-α.
Of note, we did not find evidence that STAT1 mediates the 
USP18-dependent reduction in neurogenesis. However, the tran-
scriptomics analysis shows that the Notch signaling pathway is 
regulated by both the low and the high concentrations of IFN-
α, albeit trough different molecules (see supplemental Table 6). 
This pathway is well known for its ability to govern proliferation 
and neurogenesis (Xiao et al., 2009), and USP18, via autophagic 
mechanisms, can induce Notch degradation (Xu et  al., 2015). 
Therefore, we can speculate that the USP18-induced reduction 
in neurogenesis involves the Notch signaling pathways.
We also show that IFN-α is responsible for cell apoptosis via 
STAT1-mediated production of IL-6, measured as protein in the 
supernatant of our cells. Of note, the transcriptomics analysis does 
not identify IL-6 as one of the genes regulated by IFN-α (see sup-
plemental Tables 1–3). This is not surprising, as only around 30% 
to 40% of the variance in protein abundance is explained by mRNA 
abundance (Vogel and Marcotte, 2012). Interestingly, an impor-
tant ISG, the IRF7 gene, is significantly upregulated by IFN-α (see 
supplemental Table  3). IFN-α-induced IRF7 has been previously 
shown to increase IL-6 protein secretion without influencing the 
transcripts (Sweeney, 2011), thus offering an explanation for our 
findings. Interestingly, the highest concentration of IFN-α induces 
up to 5 pg/mL of IL-6, a concentration similar to that found in both 
plasma and CSF of HCV patients who developed IFN-α-induced 
depression (Wichers et al., 2006; Raison et al., 2009), and this is the 
concentration of IL-6 that we use in our in vitro experiments. In 
contrast, in a previous study investigating the effect of IL-6 on neu-
rogenesis using our same cellular model, Johansson et al. (2008) 
used a much higher concentration of the IL-6 (50 000 pg/mL) and 
found an opposite effect on neurogenesis (Johansson et al., 2008), 
but their concentration is unlikely to be physiologically relevant. 
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Of note, in contrast with IFN-α and IL-6, USP18 decreases apopto-
sis; this is consistent with previous evidence in brain ependymal 
cells (Ritchie et al., 2002). Clearly, IL-6 must be able to overcome 
these putative protective effects of USP18.
Finally, upon the highest concentration of IFN-α and with 
IL-6 alone, we also show a downregulation of the AQP4 gene, 
again via STAT1 activation. AQP4 is important for suppress-
ing neuronal cell death (Kong et  al., 2008), possibly by involv-
ing p53-dependent signaling (Bao et  al., 2012), and, in fact, 
p53-dependent signaling pathway is regulated by the high 
concentration of IFN-α in our transcriptomics analysis. Taken 
together, these data indicate that IL-6-induced inhibition of 
AQP4 (possibly leading to changes in p53 signaling) is a potential 
mechanism through which IFN-α induces neuronal apoptosis.
Overall, our findings help clarify the molecular mechanisms 
underpinning the detrimental effects of IFN-α on both neuro-
genesis and apoptosis, and these mechanisms have transla-
tional potential. It is well known that therapeutic use of IFN-α 
is associated with many neuropsychiatric side effects, including 
depression, anxiety, and cognitive abnormalities (Raison et al., 
2005; Hepgul et  al., 2016a). Interestingly, the aforementioned 
animal studies have shown a significant upregulation of STAT1, 
ISG15, and USP18 genes in the mouse brain, including the hip-
pocampus (Wang and Campbell, 2005; Wang et al., 2008), a brain 
region involved in neurogenesis-dependent cognitive functions, 
such as memory and attention, often impaired in patients with 
depression (Moylan et  al., 2013). Indeed, postmortem stud-
ies have confirmed that patients with major depression have 
reduced hippocampal neurogenesis (Boldrini et  al., 2013) and 
that in vitro treatment with antidepressants can revert or pre-
vent this effect (Hui et al., 2014). Moreover, one study has shown 
a trend towards a greater increase in ISG15 gene expression in 
peripheral leukocytes of patients with IFN-α-induced depres-
sion (Schlaak et al., 2012). Therefore, our study and others sug-
gest that IFN-α therapy can activate IFN-stimulated molecules 
in the blood as well as in specific regions of the brain, leading 
to neurogenic alterations that are associated with cognitive and 
behavioral disturbances. We would further argue that those 
molecules might be regarded as valuable therapeutic targets for 
future treatments of neuropsychiatric disorders. IL-6 antago-
nists developed for autoimmune disorders are currently tested 
in clinical trials for depression (see, for example, ClinicalTrials.
gov identifier NCT02473289), and ISG15 inhibition has been pro-
posed as an antiviral strategy and could be repurposed for psy-
chiatric indications (Hermann and Bogunovic, 2017).
A possible limitation of our in vitro model is that the immor-
talized cell line, while being of invaluable importance for our 
understanding of molecular mechanisms occurring in the hip-
pocampus, may differ from the scenario of an adult organism 
in vivo, especially because of the absence of microglia cells. 
However, all our previous results with this in vitro model have 
been replicated by animal or clinical studies, including changes in 
neurogenesis by cortisol, IL-1, and antidepressants, and changes 
in stress- and antidepressants-regulated genes (Anacker et al., 
2011; Zunszain et al., 2012; Anacker et al., 2013a, 2013b; Horowitz 
et al., 2014; Borsini et al., 2017). Therefore, we are confident that 
our results are relevant to the human brain. Of note, we did not 
assess the effect of IFN-α on astrogliogenesis or oligodendrogen-
esis, but previous in vitro evidence has reported no changes in 
gliogenesis upon IFN-α treatment (Zheng et al., 2014).
In summary, our study reveals the ability of IFN-α to reduce 
human neurogenesis and to enhance human apoptosis in 
human hippocampal precursor cells. We also demonstrate 
a critical role of STAT1-dependent mechanisms that involve 
ISG15, USP18, and IL-6 for these effects of IFN-α. The presence 
of a cell population in the hippocampus that is highly sensitive 
to IFN-α, responding with a dramatic activation of IFN-induced 
genes, highlights the potential roles of the hippocampus in the 
IFN-α-induced psychopathology and potentially in the mecha-
nisms leading to inflammation-induced depression.
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